GlassScriptPhysician profile
Jesse W Wayson
NPI 1043835317
$717.76
in general payments reported to CMS, 2019-2025
12 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $285 · 2023: $198 · 2024: $15.71 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $433.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $153.15 | 2022-2025 | |
| Boston Scientific Corporation | $142.23 | 2022 | |
| Baxter Healthcare | $113.71 | 2022 | |
| Lsi Solutions INC | $84.71 | 2023 | Fornisee |
| Axonics, INC. | $48.21 | 2023 | Axonics |
| Bayer Healthcare Pharmaceuticals INC. | $40.95 | 2023-2025 | |
| Solventum Corporation | $30.84 | 2024-2025 | Activ.A.C., Prevena, V.A.C. Granufoam |
| Biogen, INC. | $27.06 | 2025 | Zurzuvae |
| Exeltis, USA INC. | $24.03 | 2023 | Slynd |
| Minerva Surgical, INC | $22.01 | 2025 | |
| Hologic Sales and Service, LLC | $17.17 | 2023 | Fetal Fibronectin Enzyme Immunoassay |
| Meditrina | $13.69 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Wayson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.